Control of anticoagulant therapy with portable prothrombin time device in patients with mechanical heart valve prostheses: Two-year follow-up;II trattamento anticoagulante con coagulometro portatile nei pazienti portatori di protesi valvolari meccaniche: Un follow-up di due anni

Monaldi Archives for Chest Disease

Volumn 60, Issue 4, 2003, Pages 288-294

  Tretjak, Irene ^c   Benvenuto, Gianna ^c   Drigo, Franca ^c   Casson, Michela ^c   Barocchi, Giulio ^a   Humar, Franco ^a   Pivotti, Fulvio ^a   Fisicaro, Maurizio ^a   Giansante, Carlo ^b   Scardi, Sabino ^a  

^a Centro Cardiovascolare   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Azienda Sanitari Triestina   (Italy)

Author keywords

I.N.R.; Mechanical heart valve prosthesis; Oral anticoagulants; Portable prothrombin time device

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BJOERK SHILEY VALVE PROSTHESIS; BLEEDING; CONTROLLED STUDY; CORRELATION ANALYSIS; DEVICE; DRUG SAFETY; FATALITY; FEMALE; FOLLOW UP; HEART VALVE PROSTHESIS; HUMAN; INCIDENCE; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATIENT MONITORING; PROTHROMBIN TIME; QUALITY OF LIFE; RECURRENT DISEASE; SAINT JUDE HEART VALVE PROSTHESIS; SEX DIFFERENCE; THROMBOEMBOLISM; THROMBOSIS; VALIDATION PROCESS; APPARATUS, EQUIPMENT AND SUPPLIES; INSTRUMENTATION; MONITORING; STANDARD; TIME;

ANTICOAGULANTS; EQUIPMENT AND SUPPLIES; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HEMORRHAGE; HUMANS; MALE; MONITORING, PHYSIOLOGIC; PROTHROMBIN TIME; THROMBOSIS; TIME FACTORS;

EID: 4644290522     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Kvidal P, Bergstrom R, Malm T, Stanle E. Long-term follow-up of morbidity and mortality after aortic valve replacement with a mechanical valve prosthesis. Eur Heart J 2000; 21: 1099-111.
2. Cannegieter SC, Rosendaal Fr, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. New Engl J Med 1995; 333: 11-7.
3. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001; 119: 220S-227S.
4. Calisi P, Griffo R: Anticoagulation and heart valve prosthesis. Monaldi Arch Chest Dis 2002; 58: 121-7.
5. Pengo V, Barbero F, Banzato A t al. A Comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses. Thromb Haemost 1997; 77: 839-44.
6. Scardi S, Mazzone C. La profilassi anticoagulante: Dai grandi trial alla pratica clinica. G Ital Cardiol 1997; 28: 171-83.
7. Taylor FC, Gaminara E, Cohen H, et al. Evaluation of a nurse specialist anticoagulant service. Clin Lab Haematol 1997; 19: 267-72.
8. Scardi S, Mazzone C. Alternative models of management of oral anticoagulation. Monaldi Arch Chest Dis 2002; 58: 164-9.
9. Fiane AE, Geiran OR, Svennevig JL. Up to eight years' follow-up of 997 patients receiving the Carbomedics prosthetic heart valve. Ann Thorac Sur 1998; 66: 443-8.
10. Podesser BK, Khueni-Brady G, Eigenbauer E, et al. Long-term results of heart valve replacement with the Edwards Duromedics bileaflet prosthesis: A prospective ten-year clinical follow-up. J Thorac Cardiovasc Sur 1998; 115: 1121-9.
11. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 2000; 133: 687-95.
12. Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation 2001 6; 104: 2311-7.
13. Barcellona D, Contu P, Sorano GG, et al. The management of oral anticoagulant therapy: The patient point of view. Thromb Haemost 2000; 83: 49-53.
14. Scardi S, Mazzone C. La profilassi anticoagulante: Nuove prospettive per una gestione ottimale. Card Pract Clin 1998; 3: 157-66.
15. Acar J, Enriquez-Sarano M, Farah R, et al. Recurrent systemic embolic events with valve prosthesis. Eur Heart J 1984; 5 Suppl D: 33-38.
16. Hortskotte D, Piper C, Wiemar M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998; 5: 819-24.
17. Scardi S, Baldi N, Borgioni L, et al. La profilassi anticoagulante nei portatori di protesi artificiali: Il ruolo dei centri di cardiologia sociale. Atti VIII Congresso Nazionale ANMCO, Firenze 1977: 293-5.
18. Berrettini M, Agnelli G. Management of oral anticoagulant therapy in Italy. Semin Thromb Hemost 1999; 25: 27-31.
19. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
20. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical anticoagulation control, patient outcomes, and health care. Arch Intern Med 1998; 158: 1641-7.
21. Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-management. Am Heart J 1996; 132: 1095-100.
22. Anderson Dr, Hrison L, Hirsh J. Evaluation of a portable prothronbin time monitor for home use by long-term oral anticoagulant therapy. Arch Intern Med 1993; 53: 1441-7.
23. Lesho EP, Michaud E, Asquit D. Do anticoagulant clinics treat patients more effectively than physicians? Arch Intern Med 2000; 160: 243.
24. Scardi S, Mazzone C. La profilassi anticoagulante: Nuove prospettive per una gestione ottimale. Card Pract Clin 1998; 3: 157-66.
25. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ. Community impact of anticoagulant services: Rationale a design of the managing anticoagulation services trial. J Thromb Thrombolisys 2000; 9 (Suppl 1): S7-11
26. Wenger NK: Oral anticoagulant therapy, an algorithm to facilitate control. Am J Cardiol 1996; 77: 325-6.
27. Fitzmaurice DA, Hobbs FD, Murray, et al. Evaluation of computerized decision support for oral anticoagulation management based in primary care. Br J Gen Pract 1996; 46: 533-5.
28. Manotti C, Moia M, Palareti G, et al. Effect of computer-aided management on the quality of treatment in anticoagulated patients: A prospective, randomized multicenter trial of APROAT (Automated Program for Oral Anticoagulant Treatment). Haematologica 2001; 86: 1060-70
29. Ansell JE, Buttaro ML, Thomas OV, Knowlton CH. Consensus guidelines for coordinated outpatient oral anticoagulation therapy. Anticoagulation Guidelines Task Force. Ann Pharmacother 1997; 31: 604-15.
30. Cosmi B, Palareti G, Carpanedo M, et al. Assessment of patient capability to self-adjust oral anticoagulant dose: A multicenter study on home use portable prothrombin time monitor (coaguchek). Haematologica 2000; 85: 826-31.
31. Scardi SD, Mazzone C. Il coagulometro portatile nella gestione dell'anticoagulazione. Il modello Trieste. Cardiol Pract Clin 2003, 10: 45-60.
32. White R, McCurry SA, von Marensdorff H, et al. Home prothrombin time monitoring after the initiation of warfarin therapy. Ann Intern Med 1989; 111: 730-6.
33. Tripodi A, Arbini AA, Chantarangkul V, et al. Are capillary whole blood coagulation monitors suitable for the control treatment by international normalized ratio? Thromb Haemost 1993; 70: 921-4.
34. Bernardo A. Experience with patient self-management of oral anticoagulation. J Thromb Thrombolysis 1996; 2: 321-5.
35. Scardi S, Mazzone C. La terapia anticoagulante nella pratica clinica: Le risposte a dieci domande. Roche Diagnostics, Ed Milano 2002.